
CA 19-9: A <a href="https://www.medicinenet.com/tumor_grade/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">tumor</a> marker initially found in colorectal  <a href="https://www.medicinenet.com/cancer/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">cancer</a> patients, but subsequently also identified in patients with pancreatic, stomach, and bile duct cancer. In those who have <a href="https://www.medicinenet.com/pancreatic_cancer/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">pancreatic cancer</a>, higher levels of CA 19-9 tend to be associated with more advanced disease. Noncancerous conditions that may elevate CA 19-9 levels include <a href="https://www.medicinenet.com/gallstones/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">gallstones</a>, <a href="https://www.medicinenet.com/pancreatitis/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">pancreatitis</a>, <a href="https://www.medicinenet.com/cirrhosis/article.htm" onclick="wmdTrack('embd-lnk');" rel="dt">cirrhosis</a> of the liver, and cholecystitis.